Abstract
Recommended antimicrobial treatment durations for ventilator-associated pneumonia (VAP) caused by
Pseudomonas aeruginosa have evolved over the past few decades. In this Viewpoint, we provide a narrative review of landmark trials investigating antimicrobial treatment durations for VAP caused by
P. aeruginosa, and appraise iterations of expert consensus guidelines based on these data. We highligh t strengths and weaknesses of existing data on this topic and provide recommendations for future avenues of study.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.